Variegate Porphyria (VP) Cell Models for Research

Variegate Porphyria (VP) is a rare autosomal dominant disorder caused by mutations in the PPOX gene, leading to deficiency of protoporphyrinogen oxidase. The exact prevalence is unknown but estimated at 1 in 75,000 in Europe, with higher incidence in South Africa (1 in 300) due to a founder effect. Clinical manifestations include acute neurovisceral attacks and cutaneous photosensitivity. Acute attacks can be life-threatening if untreated, but with proper management, life expectancy is normal. Chronic complications include hepatocellular carcinoma (HCC) risk, with a standardized incidence ratio of 70-fold higher than the general population (WHO, 2023).

VP serves as an excellent model for studying heme biosynthesis, porphyrin metabolism, and the interplay between metabolic pathways and cellular stress. The availability of patient-derived cell lines and the ability to generate isogenic models via CRISPR allow for mechanistic studies of PPOX mutations. Open questions include the molecular triggers for acute attacks, the role of oxidative stress in cutaneous symptoms, and the mechanisms underlying HCC predisposition. Public datasets such as ClinVar and gnomAD provide mutation frequencies, while DepMap offers dependency data for PPOX in various cancer lines.

VP is primarily a metabolic disorder, but the increased risk of HCC involves several pathways:

• • Heme biosynthesis dysregulation: PPOX deficiency leads to accumulation of protoporphyrinogen IX, which is oxidized to protoporphyrin IX, causing oxidative stress and cellular damage.
• • Oxidative stress and DNA damage: Accumulated porphyrins generate reactive oxygen species (ROS), leading to DNA mutations and activation of stress-responsive signaling.
• • Chronic inflammation and fibrosis: Repeated cutaneous and hepatic damage may promote a pro-inflammatory microenvironment, contributing to carcinogenesis.
• • Altered iron metabolism: Porphyrin accumulation can affect iron homeostasis, potentially enhancing oxidative stress and tumor promotion.

Data from TCGA (HCC) and COSMIC.

VP-related HCC involves several signaling networks:

• • Wnt/β-catenin pathway: Activating mutations in CTNNB1 lead to constitutive signaling, promoting cell proliferation.
• • MAPK/ERK pathway: Growth factor signaling is often upregulated, contributing to tumor growth.
• • PI3K/AKT/mTOR pathway: Activation promotes cell survival and metabolism.
• • Oxidative stress response: NRF2/KEAP1 pathway is often altered, affecting antioxidant defenses.

Key nodes include: β-catenin, KRAS, PIK3CA, PTEN, NRF2.

Organoids derived from patient liver or skin can recapitulate tissue architecture and metabolic functions, offering a more physiologically relevant model for studying VP.

• • PPOX knockout mice: Global knockout is embryonic lethal; conditional knockouts in liver show porphyrin accumulation and liver damage.
• • Patient-derived xenografts (PDX): Not commonly used for VP due to metabolic nature, but HCC PDX models can be used.
• • Induced models: Chemical induction with drugs like phenobarbital can trigger acute attacks in mice with partial PPOX deficiency.

CRISPR-based gene editing enables the creation of isogenic cell lines with specific PPOX mutations, providing precise models for studying VP. For example:

• • PPOX knockout cell lines: Generated by introducing frameshift mutations via CRISPR-Cas9, leading to complete loss of enzyme activity.
• • PPOX point-mutation knock-in lines: Specific patient mutations (e.g., R59W, H20P) can be introduced to study their functional impact.

These models are commercially available from various sources, sequence-verified, and can be used for drug screening, functional genomics, and mechanistic studies.

Gene-edited cell lines allow for the validation of PPOX function and the identification of modifier genes. For example, PPOX knockout lines can be used in CRISPR screens to identify genes that rescue or exacerbate porphyrin accumulation, providing insights into disease mechanisms and potential therapeutic targets.

Isogenic pairs (wild-type vs. PPOX knockout) are valuable for high-throughput screening of compounds that reduce porphyrin accumulation or protect against oxidative stress. Resistance mechanisms to heme precursors can also be studied by exposing cells to increasing concentrations of aminolevulinic acid (ALA) and selecting for resistant clones.

CRISPR synthetic lethality screens can identify genes that are essential only in PPOX-deficient cells, revealing potential drug targets. Additionally, gene-edited cells can be used to discover biomarkers for disease progression and response to therapy.